Welcome to our dedicated page for LIGAND PHARMACEUTICALS SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LIGAND PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LIGAND PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ligand Pharmaceuticals’ Chief Financial Officer, Octavio Espinoza, reported multiple stock option exercises on December 16, 2025. He acquired a total of 2,381 shares of common stock through option exercises at strike prices of $52.84, $57.22, $63.62, $92.65, and $103.42 per share. Following these transactions, he directly beneficially owned 28,567 shares of Ligand common stock. The exercised options were granted under several employee stock option awards with vesting schedules running through 2025 and expiration dates between 2028 and 2032.
Ligand Pharmaceuticals filed an update explaining that it has posted materials about its private placement investment in Athira Pharma, Inc. on its investor relations website and certain social media accounts. These posts provide more detail on the investment for interested readers.
The company also reiterates how it shares important information with the public. Ligand states that material updates may appear through SEC filings, its investor relations site, press releases, public conference calls, webcasts, its X (Twitter) account @Ligand_LGND and its LinkedIn page. Investors and other stakeholders are encouraged to review these channels regularly, and any changes to this list will be updated on the investor relations page.
Ligand Pharmaceuticals reported an insider stock sale by its chief financial officer, Octavio Espinoza. In the transaction dated 12/12/2025, he sold 1,804 shares of the company’s common stock at a price of $188.31 per share, coded as a sale in the regulatory report.
Following this transaction, Espinoza beneficially owns 26,186 shares of Ligand Pharmaceuticals common stock in direct ownership. The report is filed as an individual filing by one reporting person in his capacity as an officer and chief financial officer.
Ligand Pharmaceuticals Inc. Chief Executive Officer and director Todd C. Davis reported a bona fide gift of 130 shares of common stock on 12/04/2025.
The shares were given to a charitable entity and are reported at a price of $0.0, reflecting the gift nature of the transaction. Following this transfer, Davis directly beneficially owns 161,337 shares of Ligand common stock.
Ligand Pharmaceuticals (LGND) director John L. LaMattina reported same‑day option exercises and share sales. On 11/07/2025, he exercised 2,145 options at $66.13 and 2,034 options at $69.51, then sold 2,145 shares at $205.45 and 2,034 shares at $205.45. Following these transactions, he directly owned 30,724 shares. The options exercised were previously granted awards that had been adjusted in connection with the OmniAb Inc. separation and carried expiration dates of 05/25/2027 and 05/23/2026.
Ligand Pharmaceuticals (LGND) reported a strong Q3 2025. Total revenues and other income rose to $115.5 million from $51.8 million, led by royalties of $46.6 million and $58.2 million of contract revenue and other income.
Operating income improved to $54.9 million from $3.1 million, and non‑operating items added $86.2 million, including gains from equity‑method and other investments. Net income reached $117.3 million versus a loss a year ago, with diluted EPS of $5.68. Results included $53.1 million of income from the Pelthos transaction and higher royalties from products such as Filspari, Ohtuvayre, and Capvaxive.
The balance sheet expanded: cash and cash equivalents were $139.4 million and short‑term investments $525.1 million. The company issued $460.0 million of 2030 convertible senior notes, with $445.5 million reported as long‑term notes at quarter‑end. R&D expense increased to $21.0 million, reflecting portfolio activity. Stockholders’ equity rose to $950.2 million.
Ligand Pharmaceuticals (LGND) announced quarterly results by issuing a press release covering its financial performance for the three and nine months ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, in line with General Instruction B.2., the information is furnished rather than filed, which limits its treatment under the Exchange Act.
Ligand Pharmaceuticals (LGND): Form 4 insider transaction
Director John W. Kozarich reported open‑market sales of Ligand common stock on 11/03/2025 pursuant to a Rule 10b5‑1 trading plan adopted on March 07, 2025. Reported sales were executed in multiple trades: 84 shares at a weighted‑average price of $188.9968, 49 shares at $190.2579, 207 shares at $191.2494, and 127 shares at $192.3781. Following these transactions, the reporting person beneficially owned 44,588 shares, held directly. Prices reflect weighted averages across multiple executions within disclosed ranges.
Ligand Pharmaceuticals (LGND) reported an insider transaction by director John W. Kozarich. On 10/01/2025, he executed multiple open-market sales of common stock under a Rule 10b5-1 trading plan adopted on March 07, 2025.
Sales were small blocks of 24, 196, 155, and 92 shares at weighted-average prices of $177.6048, $178.4051, $180.0098, and $181.1838, respectively. Following these transactions, he directly beneficially owned 45,055 shares.
Footnotes state the prices reflect weighted averages across multiple trades within disclosed price ranges, with full breakdowns available upon request. The filing lists the reporting person as a Director with direct ownership.
Form 144 notice for Ligand Pharmaceuticals, Inc. (LGND) regarding proposed and recent sales of common stock. The filer reports a proposed sale of 467 shares through UBS Financial Services (Eleven Madison Avenue, New York) with an aggregate market value of $82,509.56 and an approximate sale date of 10/01/2025. The filing shows the securities were acquired on 06/09/2023 from the issuer and that payment was completed on that date. The filer also disclosed sales in the past three months by John Kozarich totaling 1,868 shares on 07/10/2025, 08/01/2025, and 09/02/2025, with reported gross proceeds of $116,750.00, $61,614.49, and $75,746.26, respectively. The filing includes the filer’s certification that they are not aware of undisclosed material adverse information.